secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mirum Pharmaceuticals, Inc. (MIRM)
CIK:        0001759425
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001759425-25-000053
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mirum Q3 revenue $133M, up 47% YoY; lifts FY guidance to $500-510M
------------------------------------------------------------------

- Q3 2025 total revenue $133.0M vs $90.4M in Q3 2024; LIVMARLI sales $92.2M (+56% YoY).
- Bile Acid Medicines net sales $40.8M, up 31% YoY; cash and investments $378M.
- Volixibat VISTAS (PSC) enrollment complete; topline data expected Q2 2026.
- Volixibat VANTAGE (PBC) and LIVMARLI EXPAND enrollment expected 2026; topline H1 2027.
- Phase 2 study of MRM-3379 for Fragile X Syndrome initiated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759425/000175942525000053/0001759425-25-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759425/000175942525000053/mirm-20251104.htm
  HTML page:      https://secwatch.observer/filing/0001759425-25-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer